Cortexyme (CRTX) Stock Price, News & Analysis

Company Overview

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $0.97 to $1.04
• 50-Day Range: $1.00 to $1.67
• 52-Week Range: $1.78 to $40.66
• Volume: 68,359 shs
• Average Volume: 620,672 shs
• Market Capitalization: $30.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRTX Stock Analysis - Frequently Asked Questions

How have CRTX shares performed this year?

Cortexyme's stock was trading at $1.85 on January 1st, 2025. Since then, CRTX stock has decreased by 44.9% and is now trading at $1.02.
View the best growth stocks for 2025 here.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) announced its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.05.

When did Cortexyme IPO?

Cortexyme (CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cortexyme investors own include Alibaba Group (BABA), Enterprise Products Partners (EPD), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Meta Platforms (META) and AT&T (T).

Company Calendar

• Last Earnings: 8/09/2021
• Today: 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:CRTX
• CIK: 1145404
• Web: www.cortexyme.com
• Phone: (650) 910-5717
• Fax: N/A
• Employees: 55
• Year Founded: 2012

Profitability

• EPS (Most Recent Fiscal Year): ($2.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-89,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.96%
• Return on Assets: -63.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.92
• Quick Ratio: 9.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.97 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 30,151,000
• Free Float: 21,739,000
• Market Cap: $30.75 million
• Optionable: Not Optionable
• Beta: 1.40